Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

1.0K
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Hypoglycemia01:26

Hypoglycemia

3
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
3
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

4.3K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

925
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
925

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial expressions of concern are infrequent even for researchers with multiple retracted publications - An observational study.

Accountability in research·2026
Same author

Agreement between self-reported fractures in a clinical trial with New Zealand Accident Compensation Corporation claims data.

The New Zealand medical journal·2026
Same author

Repeated Measurements of Vitamin D: Common and Very Unlikely to Indicate Deficiency.

Clinical endocrinology·2026
Same author

Cost-savings from fracture prevention with zoledronate in randomised controlled trials.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Is a clinician-researcher career viable in New Zealand?

The New Zealand medical journal·2026
Same author

What might a satisfactory response by journals and publishers to publication integrity concerns look like?

Reproductive biology and endocrinology : RB&E·2026
Same journal

Beyond Fracture Probability: Communicating the Full Consequences of Fracture and Contextualization.

Current osteoporosis reports·2026
Same journal

Time-Lapse HR-pQCT: an in Vivo Imaging-Based Assessment of Bone Remodeling Dynamics.

Current osteoporosis reports·2026
Same journal

Cone Beam Computed Tomography of Bonejaws in Patients With Primary Osteoporosis: A Systematic Review.

Current osteoporosis reports·2026
Same journal

Testosterone and Bone Health in Men.

Current osteoporosis reports·2026
Same journal

Stimulant Medications and Bone Health.

Current osteoporosis reports·2026
Same journal

The Innate and Adaptive Immune Functions of Osteoblast-Lineage Cells.

Current osteoporosis reports·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Diabetes medications and bone.

Andrew Grey1

  • 1Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand, a.grey@auckland.ac.nz.

Current Osteoporosis Reports
|December 1, 2014
PubMed
Summary
This summary is machine-generated.

Type 2 diabetes (T2DM) patients face higher fracture risks. Current evidence suggests non-thiazolidinedione (TZD) diabetes medications do not significantly impact bone health.

More Related Videos

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

1.7K
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

89.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K
Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

1.7K
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

89.9K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Bone Health

Background:

  • Type 2 diabetes mellitus (T2DM) is linked to increased fracture risk.
  • Thiazolidinediones (TZDs) have raised concerns regarding bone health in T2DM patients.
  • Limited data exists on other diabetes medications' skeletal effects.

Purpose of the Study:

  • To review the available evidence on the skeletal effects of non-TZD diabetes medications in T2DM.
  • To assess the clinical significance of these medications on bone health.

Main Methods:

  • Literature review of studies examining non-TZD diabetes medications and bone health.
  • Analysis of evidence quality and clinical relevance.

Main Results:

  • Scant, low-quality evidence is available for non-TZD diabetes medications.
  • Existing evidence suggests no clinically important effects on bone health.

Conclusions:

  • Current evidence does not indicate significant adverse skeletal effects from non-TZD diabetes medications.
  • Further high-quality research is needed to confirm these findings.